Current treatment for ocular myasthenia gravis

References

• Seybold ME. Myasthenia gravis. A clinical and basic science review. JAMA 250(18), 2516–2521 (1983).
   Google Scholar
• Conti-Fine BM, Milani M, Kaminski HJ. Myasthenia gravis: past, present, and future. J. Clin. Invest. 116(11), 2843–2854 (2006).
   PubMed Web of Science ®Google Scholar
• Vincent A, Palace J, Hilton-Jones D. Myasthenia gravis. Lancet 357(9274), 2122–2128 (2001).
   PubMed Web of Science ®Google Scholar
• Chang T, Gunaratne P, Gamage R, Riffsy MT, Vincent A. MuSK-antibody-positive myasthenia gravis in a South Asian population. J. Neurol. Sci. 284(1–2), 33–35 (2009).
   Google Scholar
• Evoli A, Bianchi MR, Riso R et al. Response to therapy in myasthenia gravis with anti-MuSK antibodies. Ann. NY Acad. Sci. 1132, 76–83 (2008).
   PubMed Web of Science ®Google Scholar
• Guptill JT, Sanders DB. Update on muscle-specific tyrosine kinase antibody positive myasthenia gravis. Curr. Opin. Neurol. 23(5), 530–535 (2010).
   PubMed Web of Science ®Google Scholar
• Illa I, Diaz-Manera JA, Juarez C et al. [“Seronegative” myasthenia gravis and antiMuSK positive antibodies: description of Spanish series]. Med. Clin. (Barc.) 125(3), 100–102 (2005).
   PubMed Web of Science ®Google Scholar
• Lee JY, Sung JJ, Cho JY et al. MuSK antibody-positive, seronegative myasthenia gravis in Korea. J. Clin. Neurosci. 13(3), 353–355 (2006).
   Google Scholar
• Ohta K, Shigemoto K, Fujinami A, Maruyama N, Konishi T, Ohta M. Clinical and experimental features of MuSK antibody positive MG in Japan. Eur. J. Neurol. 14(9), 1029–1034 (2007).
   Web of Science ®Google Scholar
• Higuchi O, Hamuro J, Motomura M, Yamanashi Y. Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis. Ann. Neurol. 69(2), 418–422 (2011).
   PubMed Web of Science ®Google Scholar
• Leite MI, Jacob S, Viegas S et al. IgG1 antibodies to acetylcholine receptors in 'seronegative' myasthenia gravis. Brain 131(Pt 7), 1940–1952 (2008).
   PubMedGoogle Scholar
• Inoue M, Kojima Y, Kinboshi M, Nakagawa T, Kanda M, Shibasaki H. A case of myasthenia gravis presenting solely with bulbar palsy unassociated with easy fatigability. Rinsho Shinkeigaku 53(3), 229–234 (2013).
   Google Scholar
• Zouvelou V, Papathanasiou A, Koros C, Rentzos M, Zambelis T, Stamboulis E. Pure ocular anti-musk myasthenia under no immunosuppressive treatment. Muscle Nerve 48(3), 464 (2013).
   Google Scholar
• Zouvelou V, Stamboulis E, Skriapa L, Tzartos SJ. MuSK-Ab positive myasthenia: not always grave. J. Neurol. Sci. 331(1–2), 150–151 (2013).
   Google Scholar
• Andersen JB, Engeland A, Owe JF, Gilhus NE. Myasthenia gravis requiring pyridostigmine treatment in a national population cohort. Eur. J. Neurol. 17(12), 1445–1450 (2010).
   PubMed Web of Science ®Google Scholar
• Mattis RD. Ocular manifestations of myasthenia gravis. Arch. Ophthalmol. 26, 969–982 (1941).
   Google Scholar
• Osserman KE. Myasthenia Gravis. Grune & Stratton, NY, USA (1957).
   Google Scholar
• Daroff RB. Ocular myasthenia: diagnosis and therapy. In: Neuro-ophthalmology. Glaser JS (Ed.). CV Mosby, St Louis, MO, USA, 62–71 (1980).
   Google Scholar
• Oosterhuis HJ. The ocular signs and symptoms of myasthenia gravis. Doc. Ophthalmol. 52(3–4), 363–378 (1982).
   Google Scholar
• Glaser JS, Siatkowski RM Infranuclear disorders of eye movement. In: Duane's Clinical Ophthalmology. Tasman W, Jaeger EA (Eds). Lippincott Williams & Wilkins, Philadelphia, PA, USA, 36 (1998).
   Google Scholar
• Evoli A, Tonali P, Bartoccioni E, Lo Monaco M. Ocular myasthenia: diagnostic and therapeutic problems. Acta Neurol. Scand. 77(1), 31–35 (1988).
   PubMed Web of Science ®Google Scholar
• Bever CT Jr, Aquino AV, Penn AS, Lovelace RE, Rowland LP. Prognosis of ocular myasthenia. Ann. Neurol. 14(5), 516–519 (1983).
   PubMed Web of Science ®Google Scholar
• Kaminski HJ, Maas E, Spiegel P, Ruff RL. Why are eye muscles frequently involved in myasthenia gravis? Neurology 40(11), 1663–1669 (1990).
   PubMed Web of Science ®Google Scholar
• Weinberg DA, Lesser RL, Vollmer TL. Ocular myasthenia: a protean disorder. Surv. Ophthalmol. 39(3), 169–210 (1994).
   PubMed Web of Science ®Google Scholar
• Barton JJ, Fouladvand M. Ocular aspects of myasthenia gravis. Semin. Neurol. 20(1), 7–20 (2000).
   Google Scholar
• Bhatti MT. Double trouble. Surv. Ophthalmol. 48(3), 347–355 (2003).
   Google Scholar
• Punga AR, Sawada M, Stalberg EV. Electrophysiological signs and the prevalence of adverse effects of acetylcholinesterase inhibitors in patients with myasthenia gravis. Muscle Nerve 37(3), 300–307 (2008).
   Google Scholar
• Osserman KE. Ocular myasthenia gravis. Investig. ophthalmol. 6, 277–287 (1967).
   Google Scholar
• Sieb JP, Kohler W. Benefits from sustained-release pyridostigmine bromide in myasthenia gravis: results of a prospective multicenter open-label trial. Clin. Neurol. Neurosurg. 112(9), 781–784 (2010).
   Google Scholar
• Soreq H, Seidman S. Anti-sense approach to anticholinesterase therapeutics. Isr. Med. Assoc. J. 2 Suppl, 81–85 (2000).
   Google Scholar
• Brenner T, Hamra-Amitay Y, Evron T, Boneva N, Seidman S, Soreq H. The role of readthrough acetylcholinesterase in the pathophysiology of myasthenia gravis. FASEB J. 17(2), 214–222 (2003).
   PubMed Web of Science ®Google Scholar
• Sussman JD, Argov Z, McKee D, Hazum E, Brawer S, Soreq H. Antisense treatment for myasthenia gravis: experience with monarsen. Ann. NY Acad. Sci. 1132, 283–290 (2008).
   PubMed Web of Science ®Google Scholar
• Argov Z, McKee D, Agus S et al. Treatment of human myasthenia gravis with oral antisense suppression of acetylcholinesterase. Neurology 69(7), 699–700 (2007).
   PubMed Web of Science ®Google Scholar
• Donald B. Sanders. A study to evaluate efficacy, safety and tolerability of single doses of tirasemtiv in patients with myasthenia gravis. Presented at: 65th Annual Meeting of the American Academy of Neurology conference. San Francisco, CA, USA, 16–23 March 2013.
   Google Scholar
• Brunner NG, Berger CL, Namba T, Grob D. Corticotropin and corticosteroids in generalized myasthenia gravis: comparative studies and role in management. Ann. NY Acad. Sci. 274, 577–595 (1976).
   PubMed Web of Science ®Google Scholar
• Howard FM Jr, Duane DD, Lambert EH, Daube JR. Alternate-day prednisone: preliminary report of a double-blind controlled study. Ann. NY Acad. Sci. 274, 596–607 (1976).
   Google Scholar
• Jacobson ME. The rationale of alternate-day corticosteroid therapy. Postgrad. Med. 49(2), 181–186 (1971).
   Web of Science ®Google Scholar
• Seybold ME, Drachman DB. Gradually increasing doses of prednisone in myasthenia gravis. Reducing the hazards of treatment. N. Engl. J. Med. 290(2), 81–84 (1974).
   Google Scholar
• Sghirlanzoni A, Peluchetti D, Mantegazza R, Fiacchino F, Cornelio F. Myasthenia gravis: prolonged treatment with steroids. Neurology 34(2), 170–174 (1984).
   PubMed Web of Science ®Google Scholar
• Kupersmith MJ, Moster M, Bhuiyan S, Warren F, Weinberg H. Beneficial effects of corticosteroids on ocular myasthenia gravis. Arch. Neurol. 53(8), 802–804 (1996).
   Google Scholar
• Zach H, Cetin H, Hilger E et al. The effect of early prednisolone treatment on the generalization rate in ocular myasthenia gravis. Eur. J. Neurol. 20(4), 708–713 (2013).
   Google Scholar
• Bhanushali MJ, Wuu J, Benatar M. Treatment of ocular symptoms in myasthenia gravis. Neurology 71(17), 1335–1341 (2008).
   PubMed Web of Science ®Google Scholar
• Lindberg C, Andersen O, Lefvert AK. Treatment of myasthenia gravis with methylprednisolone pulse: a double blind study. Acta Neurol. Scand. 97(6), 370–373 (1998).
   PubMed Web of Science ®Google Scholar
• Benatar M, Kaminski HJ. Evidence report: the medical treatment of ocular myasthenia (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 68(24), 2144–2149 (2007).
   Google Scholar
• Kaminski HJ, Daroff RB. Treatment of ocular myasthenia: steroids only when compelled. Arch. Neurol. 57(5), 752–753 (2000).
   Google Scholar
• Sommer N, Sigg B, Melms A et al. Ocular myasthenia gravis: response to long-term immunosuppressive treatment. J. Neurol. Neurosurg. Psychiatry 62(2), 156–162 (1997).
   PubMed Web of Science ®Google Scholar
• Skeie GO, Apostolski S, Evoli A et al. Guidelines for treatment of autoimmune neuromuscular transmission disorders. Eur. J. Neurol. 17(7), 893–902 (2010).
   PubMed Web of Science ®Google Scholar
• Haines SR, Thurtell MJ. Treatment of ocular myasthenia gravis. Curr. Treat. Options Neurol. 14(1), 103–112 (2012).
   PubMed Web of Science ®Google Scholar
• Bruce BB, Kupersmith MJ. Safety of prednisone for ocular myasthenia gravis. J. Neuroophthalmol. 32(3), 212–215 (2012).
   Google Scholar
• Benatar M, Sanders DB, Wolfe GI, McDermott MP, Tawil R. Design of the efficacy of prednisone in the treatment of ocular myasthenia (EPITOME) trial. Ann. NY Acad. Sci. 1275, 17–22 (2012).
   PubMed Web of Science ®Google Scholar
• Kuks JB, Djojoatmodjo S, Oosterhuis HJ. Azathioprine in myasthenia gravis: observations in 41 patients and a review of literature. Neuromuscul. Disord. 1(6), 423–431 (1991).
   Google Scholar
• Mantegazza R, Antozzi C, Peluchetti D, Sghirlanzoni A, Cornelio F. Azathioprine as a single drug or in combination with steroids in the treatment of myasthenia gravis. J. Neurol. 235(8), 449–453 (1988).
   PubMed Web of Science ®Google Scholar
• Matell G, Bergstrom K, Franksson C et al. Effects of some immunosuppressive procedures on myasthenia gravis. Ann. NY Acad. Sci. 274, 659–676 (1976).
   PubMedGoogle Scholar
• Mertens HG, Hertel G, Reuther P, Ricker K. Effect of immunosuppressive drugs (azathioprine). Ann. NY Acad. Sci. 377, 691–699 (1981).
   PubMedGoogle Scholar
• Witte AS, Cornblath DR, Parry GJ, Lisak RP, Schatz NJ. Azathioprine in the treatment of myasthenia gravis. Ann. Neurol. 15(6), 602–605 (1984).
   Google Scholar
• Mee J, Paine M, Byrne E, King J, Reardon K, O'Day J. Immunotherapy of ocular myasthenia gravis reduces conversion to generalized myasthenia gravis. J. Neuroophthalmol. 23(4), 251–255 (2003).
   Google Scholar
• Palace J, Newsom-Davis J, Lecky B. A randomized double-blind trial of prednisolone alone or with azathioprine in myasthenia gravis. Myasthenia Gravis Study Group. Neurology 50(6), 1778–1783 (1998).
   PubMed Web of Science ®Google Scholar
• Kissel JT, Levy RJ, Mendell JR, Griggs RC. Azathioprine toxicity in neuromuscular disease. Neurology 36(1), 35–39 (1986).
   Google Scholar
• Citterio A, Beghi E, Millul A et al. Risk factors for tumor occurrence in patients with myasthenia gravis. J. Neurol. 256(8), 1221–1227 (2009).
   Google Scholar
• Pedersen EG, Pottegard A, Hallas J et al. Use of azathioprine for non-thymoma myasthenia and risk of cancer: a nationwide case-control study in Denmark. Eur. J. Neurol. 20(6), 942–948 (2013).
   Google Scholar
• Herrlinger U, Weller M, Dichgans J, Melms A. Association of primary central nervous system lymphoma with long-term azathioprine therapy for myasthenia gravis? Ann. Neurol. 47(5), 682–683 (2000).
   PubMedGoogle Scholar
• Levin N, Abramsky O, Lossos A et al. Extrathymic malignancies in patients with myasthenia gravis. J. Neurol. Sci. 237(1–2), 39–43 (2005).
   PubMed Web of Science ®Google Scholar
• Rawoot A, Little F, Heckmann JM. Risk of malignancy in myasthenia gravis patients exposed to azathioprine therapy for a median period of 3 years. S. Afr. Med. J. 96(12), 1249–1251 (2006).
   Google Scholar
• Chaudhry V, Cornblath DR, Griffin JW, O'Brien R, Drachman DB. Mycophenolate mofetil: a safe and promising immunosuppressant in neuromuscular diseases. Neurology 56(1), 94–96 (2001).
   Google Scholar
• Meriggioli MN, Ciafaloni E, Al-Hayk KA et al. Mycophenolate mofetil for myasthenia gravis: an analysis of efficacy, safety, and tolerability. Neurology 61(10), 1438–1440 (2003).
   PubMedGoogle Scholar
• Ciafaloni E, Massey JM, Tucker-Lipscomb B, Sanders DB. Mycophenolate mofetil for myasthenia gravis: an open-label pilot study. Neurology 56(1), 97–99 (2001).
   PubMed Web of Science ®Google Scholar
• Chan JW. Mycophenolate mofetil for ocular myasthenia. J. Neurol. 255(4), 510–513 (2008).
   PubMed Web of Science ®Google Scholar
• Sanders DB, Hart IK, Mantegazza R et al. An international, phase III, randomized trial of mycophenolate mofetil in myasthenia gravis. Neurology 71(6), 400–406 (2008).
   PubMed Web of Science ®Google Scholar
• A trial of mycophenolate mofetil with prednisone as initial immunotherapy in myasthenia gravis. Neurology 71(6), 394–399 (2008).
   PubMed Web of Science ®Google Scholar
• Granelli-Piperno A. In situ hybridization for interleukin 2 and interleukin 2 receptor mRNA in T cells activated in the presence or absence of cyclosporin A. J. Exp. Med. 168(5), 1649–1658 (1988).
   Google Scholar
• Herold KC, Lancki DW, Moldwin RL, Fitch FW. Immunosuppressive effects of cyclosporin A on cloned T cells. J. Immunol. 136(4), 1315–1321 (1986).
   Google Scholar
• Kronke M, Leonard WJ, Depper JM et al. Cyclosporin A inhibits T-cell growth factor gene expression at the level of mRNA transcription. Proc. Natl Acad. Sci. USA 81(16), 5214–5218 (1984).
   Google Scholar
• Tindall RS, Rollins JA, Phillips JT, Greenlee RG, Wells L, Belendiuk G. Preliminary results of a double-blind, randomized, placebo-controlled trial of cyclosporine in myasthenia gravis. N. Engl. J. Med. 316(12), 719–724 (1987).
   PubMed Web of Science ®Google Scholar
• Tindall RS, Phillips JT, Rollins JA, Wells L, Hall K. A clinical therapeutic trial of cyclosporine in myasthenia gravis. Ann. NY Acad. Sci. 681, 539–551 (1993).
   PubMed Web of Science ®Google Scholar
• Nyberg-Hansen R, Gjerstad L. Myasthenia gravis treated with ciclosporin. Acta Neurol. Scand. 77(4), 307–313 (1988).
   Google Scholar
• Bonifati DM, Angelini C. Long-term cyclosporine treatment in a group of severe myasthenia gravis patients. J. Neurol. 244(9), 542–547 (1997).
   PubMedGoogle Scholar
• Ciafaloni E, Nikhar NK, Massey JM, Sanders DB. Retrospective analysis of the use of cyclosporine in myasthenia gravis. Neurology 55(3), 448–450 (2000).
   Google Scholar
• Heckmann JM, Rawoot A, Bateman K, Renison R, Badri M. A single-blinded trial of methotrexate versus azathioprine as steroid-sparing agents in generalized myasthenia gravis. BMC Neurol. 11, 97 (2011).
   PubMed Web of Science ®Google Scholar
• Pasnoor M, He J, Herbelin L, Dimachkie M, Barohn RJ. Phase II trial of methotrexate in myasthenia gravis. Ann. NY Acad. Sci. 1275, 23–28 (2012).
   Google Scholar
• Nowak RJ, Dicapua DB, Zebardast N, Goldstein JM. Response of patients with refractory myasthenia gravis to rituximab: a retrospective study. Ther. Adv. Neurol. Disord. 4(5), 259–266 (2011).
   PubMedGoogle Scholar
• Diaz-Manera J, Martinez-Hernandez E, Querol L et al. Long-lasting treatment effect of rituximab in MuSK myasthenia. Neurology 78(3), 189–193 (2012).
   PubMed Web of Science ®Google Scholar
• Illa I, Diaz-Manera J, Rojas-Garcia R et al. Sustained response to Rituximab in anti-AChR and anti-MuSK positive Myasthenia Gravis patients. J. Neuroimmunol. 201–202, 90–94 (2008).
   Google Scholar
• Collongues N, Casez O, Lacour A et al. Rituximab in refractory and non-refractory myasthenia: a retrospective multicenter study. Muscle Nerve 46(5), 687–691 (2012).
   PubMed Web of Science ®Google Scholar
• Lebrun C, Bourg V, Tieulie N, Thomas P. Successful treatment of refractory generalized myasthenia gravis with rituximab. Eur. J. Neurol. 16(2), 246–250 (2009).
   Google Scholar
• Jani-Acsadi A, Lisak RP. Myasthenia gravis. Curr. Treat. Options Neurol. 12(3), 231–243 (2010).
   PubMed Web of Science ®Google Scholar
• Sanders DB, Evoli A. Immunosuppressive therapies in myasthenia gravis. Autoimmunity 43(5–6), 428–435 (2010).
   PubMed Web of Science ®Google Scholar
• Furukawa Y, Yoshikawa H, Iwasa K, Yamada M. Clinical efficacy and cytokine network-modulating effects of tacrolimus in myasthenia gravis. J. Neuroimmunol. 195(1–2), 108–115 (2008).
   Google Scholar
• Yoshikawa H, Kiuchi T, Saida T, Takamori M. Randomised, double-blind, placebo-controlled study of tacrolimus in myasthenia gravis. J. Neurol. Neurosurg. Psychiatry 82(9), 970–977 (2011).
   PubMed Web of Science ®Google Scholar
• Minami N, Fujiki N, Doi S et al. Five-year follow-up with low-dose tacrolimus in patients with myasthenia gravis. J. Neurol. Sci. 300(1–2), 59–62 (2011).
   PubMed Web of Science ®Google Scholar
• Soliven B, Rezania K, Gundogdu B, Harding-Clay B, Oger J, Arnason BG. Terbutaline in myasthenia gravis: a pilot study. J. Neurol. Sci. 277(1–2), 150–154 (2009).
   Google Scholar
• Lashley D, Palace J, Jayawant S, Robb S, Beeson D. Ephedrine treatment in congenital myasthenic syndrome due to mutations in DOK7. Neurology 74(19), 1517–1523 (2010).
   Google Scholar
• Khatri BO, Koethe SM, McQuillen MP. Plasmapheresis with immunosuppressive drug therapy in progressive multiple sclerosis. A pilot study. Arch. Neurol. 41(7), 734–738 (1984).
   Google Scholar
• Yeh JH, Wang SH, Chien PJ, Shih CM, Chiu HC. Changes in serum cytokine levels during plasmapheresis in patients with myasthenia gravis. Eur. J. Neurol. 16(12), 1318–1322 (2009).
   Google Scholar
• Barth D, Nabavi Nouri M, Ng E, Nwe P, Bril V. Comparison of IVIg and PLEX in patients with myasthenia gravis. Neurology 76(23), 2017–2023 (2011).
   PubMed Web of Science ®Google Scholar
• Balogun RA, Kaplan A, Ward DM et al. Clinical applications of therapeutic apheresis. J. Clin. Apher. 25(5), 250–264 (2010).
   Google Scholar
• Ebadi H, Barth D, Bril V. Safety of plasma exchange therapy in patients with myasthenia gravis. Muscle Nerve 47(4), 510–514 (2013).
   PubMed Web of Science ®Google Scholar
• Calvert PC Disorders of neuromuscular transmission. In: Walsh and Hoyt's Clinical Neuro-Ophthalmology (6th Edition). Miller NR, Newman NJ, Biousse V, Kerrison JB (Eds). Lippincott Williams & Wilkins, Philadelphia, PA, USA Maryland, USA: Williams and Wilkins, 1041–1065 (2005).
   Google Scholar
• Nakamura H, Taniguchi Y, Suzuki Y et al. Delayed remission after thymectomy for myasthenia gravis of the purely ocular type. J. Thorac. Cardiovasc. Surg. 112(2), 371–375 (1996).
   Google Scholar
• Asamura S, Kakizaki H, Enjyo M, Hashimoto T, Isogai N. Frontalis sling procedure for ocular myasthenia gravis. Clin. Ophthalmol. 6, 575–577 (2012).
   Google Scholar
• Bernardini FP, de Conciliis C, Devoto MH. Frontalis suspension sling using a silicone rod in patients affected by myogenic blepharoptosis. Orbit 21(3), 195–198 (2002).
   PubMedGoogle Scholar
• Bradley EA, Bartley GB, Chapman KL, Waller RR. Surgical correction of blepharoptosis in patients with myasthenia gravis. Ophthal. Plast. Reconstr. Surg. 17(2), 103–110 (2001).
   PubMed Web of Science ®Google Scholar
• Carter SR, Meecham WJ, Seiff SR. Silicone frontalis slings for the correction of blepharoptosis: indications and efficacy. Ophthalmology 103(4), 623–630 (1996).
   PubMed Web of Science ®Google Scholar
• Castronuovo S, Krohel GB, Kristan RW. Blepharoptosis in myasthenia gravis. Ann. Ophthalmol. 15(8), 751–754 (1983).
   Google Scholar
• Kapetansky DI. Surgical correction of blepharoptosis in myasthenia gravis. Am. J. Ophthalmol. 74(5), 818–820 (1972).
   Google Scholar
• Yu CC, Chen SG, Chen TM. Frontalis slings with palmaris tendon as an adjuvant treatment for myasthenic blepharoptosis: a case report. Ann. Plast. Surg. 58(5), 577–579 (2007).
   Google Scholar
• Nagane Y, Utsugisawa K, Suzuki S et al. Topical naphazoline in the treatment of myasthenic blepharoptosis. Muscle Nerve 44(1), 41–44 (2011).
   Google Scholar
• Bentley CR, Dawson E, Lee JP. Active management in patients with ocular manifestations of myasthenia gravis. Eye (Lond) 15(Pt 1), 18–22 (2001).
   Google Scholar
• Ohtsuki H, Hasebe S, Okano M, Furuse T. Strabismus surgery in ocular myasthenia gravis. Ophthalmologica 210(2), 95–100 (1996).
   Google Scholar
• Davidson JL, Rosenbaum AL, McCall LC. Strabismus surgery in patients with myasthenia. J. Pediatr. Ophthalmol. Strabismus 30(5), 292–295 (1993).
   Google Scholar
• Morris OC. O'Day J. Strabismus surgery in the management of diplopia caused by myasthenia gravis. Br. J. Ophthalmol. 88(6), 832 (2004).
   Google Scholar
• Park KA, Oh SY. Treatment for diplopia in patients with myasthenia gravis. Graefes Arch. Clin. Exp. Ophthalmol. 251(3), 895–901 (2013).
   Google Scholar
• Acheson JF, Elston JS, Lee JP, Fells P. Extraocular muscle surgery in myasthenia gravis. Br. J. Ophthalmol. 75(4), 232–235 (1991).
   Google Scholar